Thermo Fisher Scientific Inc. will acquire drug development and delivery services provider Patheon NV for $7.2 billion, including $2 billion of debt assumption. Diagnostics and laboratory-focused Thermo Fisher expects that the addition of the Durham, N.C.-based contract development and manufacturing organization (CDMO) will add to its offerings for biopharmaceutical customers.
A tissue treatment device that can participate in the biotech-driven immuno-oncology fervor of the last few years may sound too good to be true. That's precisely the case being made by long-short hedge fund Kerrisdale Capital Management LLC, which has issued a report critical of the science behind early stage Pulse Biosciences Inc. and holds a short position betting against it. During February and March, the Burlingame, Calif.-based company saw its valuation jump from less than $100 million to more than $450 million after high-profile investors Robert Duggan and Mahkam Zanganeh, respectively the former CEO...
A tissue treatment device that can participate in the biotech-driven immuno-oncology fervor of the last few years may sound too good to be true. That's precisely the case being made by long-short hedge fund Kerrisdale Capital Management LLC, which has issued a report critical of the science behind early stage Pulse Biosciences Inc. and holds a short position betting against it.
Cerus Corp. is optimistic that its Intercept blood system will become the standard of care in the U.S. when it comes to pathogen reduction in donor plasma and platelets. But it's been more than a couple of years since the Concord, Calif.-based company first won FDA approval in those indications. Now, it's working on a phase III clinical trial program aimed at expanding the technology's application into the broader market for pathogen reduction in red blood cells (RBCs) by the end of the decade. Cerus is also awaiting a final FDA guidance on bacterial safety...
Cerus Corp. is optimistic that its Intercept blood system will become the standard of care in the U.S. when it comes to pathogen reduction in donor plasma and platelets. But it's been more than a couple of years since the Concord, Calif.-based company first won FDA approval in those indications.
Livanova plc sees transcatheter mitral valve replacement (TMVR) is coming up next as a multibillion segment following on TAVR. To secure what it expects will be market-leading technology, the London-based company has acquired Maple Grove, Minn.-based Caisson Interventional LLC. Sorin SpA and Cyberonics Inc. merged in the fall of 2015 to become Livanova; Sorin had been a Caisson investor since 2012. Livanova has acquired the remaining 51 percent of Caisson for $78 million in cash, milestones and debt forgiveness. APPROACH ADVANTAGE? Caisson's TMVR implant is the only one designed entirely for use via a transseptal...
Livanova plc sees transcatheter mitral valve replacement (TMVR) is coming up next as a multibillion segment following on TAVR. To secure what it expects will be market-leading technology, the London-based company has acquired Maple Grove, Minn.-based Caisson Interventional LLC.
Hedge fund giant KKR sees opportunity in a new investment approach to the medical device space. Alongside life science private equity player Aisling Capital, KKR has created Ajax Health to enable it to provide financial and operational support to medical device companies. MED-TECH OPPORTUNITY It aims to opportunistically invest in roughly seven to 10 device companies that have only one or two significant remaining risks until they reach a major inflection point. Roughly $15 million to $30 million will be invested in total for each company. The first Ajax company is Advanced Cardiac Therapeutics Inc....
Hedge fund giant KKR sees opportunity in a new investment approach to the medical device space. Alongside life science private equity player Aisling Capital, KKR has created Ajax Health to enable it to provide financial and operational support to medical device companies.
